First In-Room MRI-Guided Breast Biopsy System Gets FDA Clearance

Key Takeaways

• First FDA‑cleared in‑room MR breast biopsy system
• Reduces procedure steps by eliminating patient transfers
• 8‑gauge needle collects larger tissue samples
• Tubing length cut 75%, speeding setup/cleanup
• HydroMARK Plus markers visible across MRI, ultrasound, mammography

Pulse Analysis

MRI‑guided breast biopsy is reserved for lesions invisible on mammography, especially in dense‑breasted or high‑risk patients. Traditional workflows require moving the patient from the scanner to a separate procedure room, coordinating imaging and surgical teams, and managing lengthy setup times. These steps increase procedural cost, extend patient time under anesthesia, and raise the risk of targeting errors, limiting the overall efficiency of breast cancer diagnostics. Moreover, the need to reposition the patient can cause discomfort and increase the risk of motion artifacts, further compromising image quality.

Mammotome’s newly cleared Prima MR system brings the biopsy device directly into the MRI suite, eliminating patient transfers. The 8‑gauge vacuum‑assisted needle captures larger, contiguous tissue cores, while 75 % less tubing shortens setup and cleanup. A touchscreen interface lets clinicians adjust aperture size and vacuum strength on the fly, improving targeting precision. The intuitive touchscreen reduces the learning curve for radiologists, facilitating faster adoption across busy imaging departments. Combined with HydroMARK Plus markers that remain visible on MRI, ultrasound and mammography, the platform promises higher diagnostic yield and fewer repeat procedures.

The clearance positions Mammotome to capture a growing segment of the breast‑diagnostic market, where hospitals seek to streamline costly MRI‑guided workflows. By cutting procedure time and improving sample quality, the system can lower overall care costs and enhance patient satisfaction—key metrics for value‑based reimbursement models. As competitors race to integrate imaging and intervention, Mammotome’s early mover advantage and its dual‑marker solution may set a new standard for MRI‑guided biopsies worldwide. International rollouts slated for later this year will test the system’s adaptability to varied regulatory environments, while insurers may favor the technology for its potential to reduce repeat biopsies and associated expenses.